CA2281049A1 - Water-soluble pharmaceutical composition in an ionic complex and the use thereof - Google Patents
Water-soluble pharmaceutical composition in an ionic complex and the use thereof Download PDFInfo
- Publication number
- CA2281049A1 CA2281049A1 CA002281049A CA2281049A CA2281049A1 CA 2281049 A1 CA2281049 A1 CA 2281049A1 CA 002281049 A CA002281049 A CA 002281049A CA 2281049 A CA2281049 A CA 2281049A CA 2281049 A1 CA2281049 A1 CA 2281049A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- composition
- complex
- amphiphilic compound
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Abstract
A water-soluble composition containing a complex of an ionic pharmaceutically effective polypeptide selected from the group consisting of hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, characterized in that said composition contains, in addition, an amphiphilic compound, said polypeptide and said amphiphilic compound forming an ionic complex, whereby the forming of the complex does not enhance the solubility of said polypeptide, is suitable for increasing the activity of the polypeptide and/or for the delayed release of the polypeptide.
Claims (11)
1. An aqueous composition containing a pharmaceutically effective polypeptide selected from the group consisting of hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, characterized in that said composition contains, in addition, an amphiphilic compound, said polypeptide and said amphiphilic compound forming an ionic complex, whereby the forming of the complex does not enhance the solubility of said polypeptide.
2. Composition as claimed in claim 1 in lyophilized form.
3. Composition as claimed in claim 2, wherein the complex is immobilized on a biocompatible carrier.
4. Composition as claimed in claim 3, wherein the complex is present in a mixture of a dissolved and precipitated form.
5. Composition as claimed in claims 1 to 4, wherein said composition has a pH
value in an aqueous solution which differs by at least one half pH unit from the pK
values of the polypeptide and of said surfactant.
value in an aqueous solution which differs by at least one half pH unit from the pK
values of the polypeptide and of said surfactant.
6. Composition as claimed in claims 1 to 5, wherein said polypeptide is hedgehog protein.
7. Composition as claimed in claims 1 to 6, wherein the amphiphilic compound is deoxycholate.
8. Use of a composition as claimed in claims 1 to 7 for the delayed release or local application of the hedgehog protein in the human body.
9. Process for the production of a pharmaceutical composition for local application in humans, wherein a complex of a pharmaceutically effective polypeptide selected from the group consisting of hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, and of an amphiphilic compound formed by ionic interaction is used as an essential component, in which the auxiliary compound is present at a concentration which does not enhance the water-solubility of said polypeptide.
10. Process as claimed in claim 9, characterized in that the complex is immobilized on a biocompatible carrier.
11. Method for increasing the activity of a polypeptide which is recognized and bound by a cell surface receptor, characterized by forming an ionic complex between said polypeptide and an amphiphilic compound.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98116494 | 1998-09-01 | ||
EP98116494.0 | 1998-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2281049A1 true CA2281049A1 (en) | 2000-03-01 |
CA2281049C CA2281049C (en) | 2010-11-02 |
Family
ID=8232558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2281049A Expired - Fee Related CA2281049C (en) | 1998-09-01 | 1999-08-30 | Water-soluble pharmaceutical composition in an ionic complex and the use thereof |
Country Status (30)
Country | Link |
---|---|
US (3) | US6867182B2 (en) |
EP (1) | EP1002547B1 (en) |
JP (1) | JP3664373B2 (en) |
KR (1) | KR100403075B1 (en) |
CN (1) | CN1325118C (en) |
AR (1) | AR023044A1 (en) |
AT (1) | ATE318616T1 (en) |
AU (1) | AU755930B2 (en) |
BR (1) | BR9903984B1 (en) |
CA (1) | CA2281049C (en) |
CO (1) | CO5271726A1 (en) |
DE (1) | DE69930033T2 (en) |
ES (1) | ES2258830T3 (en) |
GC (1) | GC0000107A (en) |
HR (1) | HRP990272B1 (en) |
HU (1) | HUP9902952A1 (en) |
ID (1) | ID22964A (en) |
IL (1) | IL131626A0 (en) |
MA (1) | MA26682A1 (en) |
MY (1) | MY127935A (en) |
NO (1) | NO994214L (en) |
NZ (1) | NZ337527A (en) |
PE (1) | PE20001027A1 (en) |
PL (1) | PL194218B1 (en) |
RU (1) | RU2180855C2 (en) |
SG (1) | SG85670A1 (en) |
TR (1) | TR199902103A2 (en) |
TW (1) | TW570805B (en) |
YU (1) | YU42399A (en) |
ZA (1) | ZA995601B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050112087A1 (en) * | 2003-04-29 | 2005-05-26 | Musso Gary F. | Pharmaceutical formulations for sustained drug delivery |
US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
EA009676B1 (en) * | 2003-06-10 | 2008-02-28 | Эл Джи Лайф Сайенсиз Лтд. | Aqueous formulation of human erythropoietin |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
TR201802446T4 (en) * | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Injectable composition containing sodium deoxycholate. |
WO2007010900A1 (en) * | 2005-07-15 | 2007-01-25 | Transcu Ltd. | Percutaneous absorption patch with application position indicating function, and iontophoresis device |
JP2007037868A (en) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | Transdermal administration device and its controlling method |
US20070042041A1 (en) * | 2005-08-17 | 2007-02-22 | Board Of Trustees Of The University Of Arkansas | Drug-surfactant complexes for sustained release |
EP1925335A1 (en) * | 2005-09-16 | 2008-05-28 | Tti Ellebeau, Inc. | Catheter type iontophoresis apparatus |
RU2008117153A (en) * | 2005-09-30 | 2009-11-10 | ТиТиАй ЭЛЛЕБО, ИНК. (JP) | IONTOPHORESIS DEVICE DELIVERING MANY ACTIVE AGENTS TO BIOLOGICAL BARRIERS |
US20080033338A1 (en) * | 2005-12-28 | 2008-02-07 | Smith Gregory A | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
WO2007079193A2 (en) * | 2005-12-30 | 2007-07-12 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
US20080004564A1 (en) * | 2006-03-30 | 2008-01-03 | Transcutaneous Technologies Inc. | Controlled release membrane and methods of use |
CA2655164A1 (en) * | 2006-07-05 | 2008-01-10 | Tti Ellebeau, Inc. | Delivery device having self-assembling dendritic polymers and method of use thereof |
ES2542146T3 (en) | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | PEGylated extended insulin. |
BRPI0717098B8 (en) | 2006-09-22 | 2021-05-25 | Novo Nordisk As | protease-resistant human insulin analogues, pharmaceutical composition and process for their preparation |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
FR2908414B1 (en) | 2006-11-13 | 2012-01-20 | Centre Nat Rech Scient | IMMOBILIZATION OF MEMBRANE PROTEINS ON A SUPPORT THROUGH AN AMPHIPHILE MOLECULE |
EP2123259A1 (en) * | 2007-01-16 | 2009-11-25 | Hokkaido University | Liposome preparation for iontophoresis having antioxidant component encapsulated therein |
JP5496082B2 (en) | 2007-04-30 | 2014-05-21 | ノボ・ノルデイスク・エー/エス | Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein |
JP5628026B2 (en) * | 2007-06-01 | 2014-11-19 | ノボ・ノルデイスク・エー/エス | Stable non-aqueous pharmaceutical composition |
JP2010187707A (en) * | 2007-06-12 | 2010-09-02 | Hokkaido Univ | Liposome preparation for iontophoresis comprising insulin encapsulated therein |
EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
BRPI0910348B1 (en) | 2008-03-18 | 2021-06-29 | Novo Nordisk A/S | INSULIN STABILIZED IN ACILLED PROTEASE, PHARMACEUTICAL COMPOSITION INCLUDING IT AND ITS USES |
US20100069877A1 (en) * | 2008-09-10 | 2010-03-18 | Smith Gregory A | Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process |
WO2012134540A2 (en) * | 2010-10-22 | 2012-10-04 | Vanderbilt University | Injectable synthetic pur composite |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
CN102762224A (en) * | 2009-12-22 | 2012-10-31 | 塞尔德克斯医疗公司 | Vaccine compositions |
EP2675460A4 (en) | 2011-02-18 | 2014-07-09 | Kythera Biopharmaceuticals Inc | Treatment of submental fat |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
JP6224069B2 (en) | 2012-03-23 | 2017-11-01 | アミクローブ,インコーポレイテッド | Compositions and uses of antibacterial agents with histocompatibility properties |
KR20150002777A (en) | 2012-04-11 | 2015-01-07 | 노보 노르디스크 에이/에스 | Insulin formulations |
ES2676065T3 (en) | 2013-10-07 | 2018-07-16 | Novo Nordisk A/S | New derivative of an insulin analog |
KR101945498B1 (en) * | 2015-11-04 | 2019-02-08 | 포항공과대학교 산학협력단 | Composition for skin permeation comprising cationic molecular transporters and protein |
IL300839B2 (en) | 2016-12-16 | 2024-04-01 | Novo Nordisk As | Insulin containing pharmaceutical compositions |
CN110740744A (en) | 2017-04-06 | 2020-01-31 | 艾麦克罗比公司 | Compositions and uses of topically applied antimicrobial agents with enhanced performance and safety |
US11198831B2 (en) | 2019-01-31 | 2021-12-14 | Kvi Llc | Lubricant for a device |
TW202102266A (en) * | 2019-04-01 | 2021-01-16 | 美商建南德克公司 | Compositions and methods for stabilizing protein-containing formulations |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61500790A (en) | 1984-03-28 | 1986-04-24 | シタス コ−ポレイシヨン | Composition containing microbially produced interleukin-2 |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
LU85971A1 (en) * | 1985-06-25 | 1987-01-13 | Oreal | NOVEL AMPHIPHILIC LIPID COMPOUNDS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS, ESPECIALLY IN COSMETICS AND DERMOPHARMACY |
JPS62207226A (en) | 1986-03-07 | 1987-09-11 | Sumitomo Pharmaceut Co Ltd | Pharmaceutical for nasotracheal administration |
FR2615194B1 (en) * | 1987-05-11 | 1991-06-14 | Rhone Poulenc Chimie | COMPRISING POLYMER PARTICLES IMPLANTED ON THE SURFACE OF AMPHIPHILIC MOLECULES CARRYING IONOGENIC OR REAGENT GROUPS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN BIOLOGY |
DE68927479T2 (en) * | 1988-05-02 | 1997-04-03 | Phanos Tech Inc | CONNECTIONS, COMPOSITIONS AND METHOD FOR BINDING ORGANIC AFFECTION SUBSTANCES TO SURFACE MEMBRANES OF BIOPARTICLES |
US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
FR2694559B1 (en) * | 1992-08-06 | 1994-10-28 | Atta | New amphiphilic derivatives of amino acids or peptides, their preparation process and their use in preparations for biomedical use. |
AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
JP3290745B2 (en) | 1993-03-31 | 2002-06-10 | 藤平 正道 | Method for forming monolayer pattern |
IS1796B (en) * | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
US5789543A (en) * | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
WO1995018856A1 (en) * | 1993-12-30 | 1995-07-13 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
US20030186357A1 (en) * | 1993-12-30 | 2003-10-02 | Philip W. Ingham | Vertebrate embryonic pattern-inducing proteins, and uses related thereto |
FR2714621B1 (en) | 1994-01-06 | 1996-02-23 | Centre Nat Rech Scient | Process for the preparation of liposomes without using an organic solvent. |
GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
US5750123A (en) * | 1996-06-28 | 1998-05-12 | Chesebrough-Pond's Co., Division Of Conopco, Inc. | Vitamin C delivery system |
EP0966478A4 (en) * | 1996-10-07 | 2002-08-21 | Univ Johns Hopkins Med | Novel hedgehog-derived polypeptides |
CN1233257A (en) | 1996-10-15 | 1999-10-27 | 生化学工业株式会社 | Polypeptide transition metal salts and method of enhancing anti-HIV activity of polypeptide |
WO1998020298A1 (en) * | 1996-11-08 | 1998-05-14 | Northern Magnetics, Inc. | Sensing and controlling the location of elements of a linear motor |
US5759811A (en) * | 1996-11-13 | 1998-06-02 | The Regents Of The University Of California | Mutant human hedgehog gene |
JPH10194987A (en) * | 1997-01-14 | 1998-07-28 | Youtai Iwamoto | Composition for ossification and chondrogenesis |
JPH114695A (en) * | 1997-04-25 | 1999-01-12 | Hayashibara Biochem Lab Inc | Hedgehog protein |
US6639051B2 (en) * | 1997-10-20 | 2003-10-28 | Curis, Inc. | Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
DK0917879T3 (en) | 1997-11-22 | 2002-11-04 | Roche Diagnostics Gmbh | Improved protein stabilization method |
EP0919618A1 (en) | 1997-11-28 | 1999-06-02 | Boehringer Mannheim Gmbh | Active Hedgehog protein mutants, methods of production and application |
CN1294595A (en) | 1997-12-03 | 2001-05-09 | 生物基因公司 | Hydrophobically-modified protein compsns, and methods |
JP3648051B2 (en) * | 1998-02-02 | 2005-05-18 | 富士通株式会社 | Related information retrieval apparatus and program recording medium |
EP0947201B1 (en) * | 1998-02-04 | 2006-06-28 | Curis, Inc. | Pharmaceutical composition of hedgehog proteins and use thereof |
CA2260423C (en) | 1998-02-04 | 2006-06-20 | Kurt Lang | Pharmaceutical composition of hedgehog proteins and use thereof |
EP0953576B1 (en) * | 1998-04-30 | 2005-11-02 | Curis, Inc. | Active hedgehog protein conjugate, process for its production and use |
US20050021440A1 (en) * | 2003-04-04 | 2005-01-27 | Scott Dresden | Integrated dynamic pricing and procurement support for e-commerce advertising channels |
US20070203906A1 (en) * | 2003-09-22 | 2007-08-30 | Cone Julian M | Enhanced Search Engine |
US20050114319A1 (en) * | 2003-11-21 | 2005-05-26 | Microsoft Corporation | System and method for checking a content site for efficacy |
US10515374B2 (en) * | 2005-03-10 | 2019-12-24 | Adobe Inc. | Keyword generation method and apparatus |
-
1999
- 1999-08-18 TW TW088114073A patent/TW570805B/en not_active IP Right Cessation
- 1999-08-24 EP EP99116537A patent/EP1002547B1/en not_active Expired - Lifetime
- 1999-08-24 ES ES99116537T patent/ES2258830T3/en not_active Expired - Lifetime
- 1999-08-24 AT AT99116537T patent/ATE318616T1/en active
- 1999-08-24 DE DE69930033T patent/DE69930033T2/en not_active Expired - Lifetime
- 1999-08-27 IL IL13162699A patent/IL131626A0/en unknown
- 1999-08-27 CN CNB991192451A patent/CN1325118C/en not_active Expired - Fee Related
- 1999-08-27 ID IDP990812D patent/ID22964A/en unknown
- 1999-08-27 CO CO99054477A patent/CO5271726A1/en not_active Application Discontinuation
- 1999-08-27 SG SG9904209A patent/SG85670A1/en unknown
- 1999-08-27 NZ NZ337527A patent/NZ337527A/en unknown
- 1999-08-27 MY MYPI99003715A patent/MY127935A/en unknown
- 1999-08-28 KR KR10-1999-0036053A patent/KR100403075B1/en not_active IP Right Cessation
- 1999-08-30 YU YU42399A patent/YU42399A/en unknown
- 1999-08-30 CA CA2281049A patent/CA2281049C/en not_active Expired - Fee Related
- 1999-08-30 GC GCP1999255 patent/GC0000107A/en active
- 1999-08-30 AR ARP990104345A patent/AR023044A1/en not_active Application Discontinuation
- 1999-08-31 ZA ZA9905601A patent/ZA995601B/en unknown
- 1999-08-31 RU RU99118890/14A patent/RU2180855C2/en active
- 1999-08-31 MA MA25748A patent/MA26682A1/en unknown
- 1999-08-31 NO NO994214A patent/NO994214L/en not_active Application Discontinuation
- 1999-08-31 HR HR990272A patent/HRP990272B1/en not_active IP Right Cessation
- 1999-08-31 TR TR1999/02103A patent/TR199902103A2/en unknown
- 1999-08-31 AU AU44866/99A patent/AU755930B2/en not_active Ceased
- 1999-08-31 PE PE1999000871A patent/PE20001027A1/en not_active Application Discontinuation
- 1999-09-01 HU HU9902952A patent/HUP9902952A1/en unknown
- 1999-09-01 JP JP24801399A patent/JP3664373B2/en not_active Expired - Lifetime
- 1999-09-01 BR BRPI9903984-2A patent/BR9903984B1/en not_active IP Right Cessation
- 1999-09-01 PL PL335203A patent/PL194218B1/en unknown
-
2001
- 2001-09-17 US US09/953,721 patent/US6867182B2/en not_active Expired - Lifetime
-
2005
- 2005-01-10 US US11/032,492 patent/US20050123610A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/931,118 patent/US8519098B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2281049A1 (en) | Water-soluble pharmaceutical composition in an ionic complex and the use thereof | |
RU99118890A (en) | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION IN THE FORM OF ION COMPLEX AND ITS APPLICATION | |
EP0301639A3 (en) | Analogues of the bradykinin potentiating peptide bpp 5a and methods for their preparation | |
RU2004127916A (en) | METHOD FOR INTRODUCING GLP-1 MOLECULES | |
AU1819088A (en) | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
AR240251A1 (en) | METHOD TO PREPARE A COMPOSITION FOR TREATMENT OF VIRAL INFECTIONS AND A METHOD TO SYNTHESIZE 3 'AZIDO 2', 3 'DIDEOXIURIDINA INTENDED FOR THE PREPARATION OF SUCH COMPOSITION. | |
CA2123048A1 (en) | Tetrazole derivatives of bile acids, processes for their preparation and the use of these compounds as medicaments | |
CA2081356A1 (en) | Derivatives and analogues of 2-deoxy-2,3-didehydro-n- acetyl neuraminic acid and their use as antiviral agents | |
HUT51254A (en) | Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient | |
WO1997009343A3 (en) | Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers | |
CA2446435A1 (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives | |
CA2372339A1 (en) | Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction | |
CA2152907A1 (en) | Antiviral topical pharmaceutical compositions | |
CA2151957A1 (en) | Aqueous pharmaceutical preparations of g-csf which are stable in storage | |
CA2468916A1 (en) | A stable oxaliplatin solution formulation | |
EP0198388A3 (en) | Enterally effective biologically active peptide or protein composition, method for the production thereof, and a pharmaceutical composition containing same | |
FR2766368B1 (en) | METHOD FOR PREPARING NANOCAPSULES OF THE VESICULAR TYPE, USABLE IN PARTICULAR AS COLLOIDAL VECTORS OF PHARMACEUTICAL OR OTHER ACTIVE PRINCIPLES | |
KR960021061A (en) | Pharmaceutical Compositions for Oral Administration | |
AU5007196A (en) | Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them | |
FR2743075B1 (en) | PROCESS FOR THE PREPARATION OF ACTIVE SUBSTANCES FROM NACRE, PRODUCTS OBTAINED, USEFUL IN PARTICULAR AS MEDICAMENTS | |
EP0992509A3 (en) | Novel macrolide derivatives | |
HUP9903459A3 (en) | Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same | |
CA2139509A1 (en) | Process for the preparation of iodinated biopolymers having disinfectant and cicatrizing activity, and the iodinated biopolymers obtainable thereby | |
HUT51221A (en) | Process for producing pharmaceutical compositions comprising 3-demethyl-4-fluoromevalonic acid derivatives and the active ingredients | |
FR2613223B1 (en) | GALENIC FORM PRESENTING IN THE FORM OF WATER-SOLUBLE GRAINS, PARTICULARLY BASED ON A DRY GINKGO BILOBA EXTRACT, AND ITS PREPARATION METHOD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150831 |